Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday

Valeant prescription drugs International opposition. is scheduled  to unharness earnings before Tuesday's open. The stock hit a record high of $263.81/share in 2015 and is presently commercialism close to $11/share. The stock is at risk of massive moves once reportage earnings and may simply gap up if the numbers area unit robust. Conversely, if the numbers frustrate, the stock will simply gap down. to assist you prepare, here is what the road is expecting:

Valeant prescription drugs is predicted to earn $0.91/share on $2.17 billion in revenue. Meanwhile, the alleged Whisper range is $0.93. The Whisper range is that the Street's unofficial read on earnings.


Company Profile & numerous Businesses:

Here could be a temporary company profile courtesy of Thomson Reuters Eikon:

Valeant prescription drugs International, Inc., incorporated on August nine, 2013, could be a specialty pharmaceutical and medical device company. the corporate is engaged in developing, producing, and promoting a variety of branded, generic and branded generic prescription drugs, over-the-counter (OTC) merchandise, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical instrumentation and aesthetics devices), that area unit marketed directly or indirectly in over one hundred countries. the corporate operates through 2 segments: Developed markets and rising markets. within the Developed Markets section, it focuses on the areas of medicine, neurology, duct (GI) disorders, and eye health therapeutic categories. within the rising Markets section, it focuses totally on branded generics, over-the-counter merchandise and medical devices.